<DOC>
	<DOCNO>NCT00500461</DOCNO>
	<brief_summary>GSK233705 develop treatment chronic obstructive pulmonary disease . This open-label , dose-ascending study 7 healthy male subject establish well tolerated intravenous dos oral dose GSK233705 . The main objective study confirm IV oral dose definitive human radiolabel metabolic study .</brief_summary>
	<brief_title>Study To Examine Safety , Tolerability And Pharmacokinetics Of Intravenous Doses And Oral Dose Of GSK233705</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Healthy male subject ; Between age 1855 year , inclusive Body mass index within range 18.0 30.0 kg/m2 . Nonsmokers Adequate venous access intermittent cannulation A sign date write informed consent obtain subject The subject capable give informed consent Available complete study Any clinically important abnormality identify follow : screen medical assessment A mean QTc ( B ) value screen &gt; 450msec , QTc ( B ) 3 screen ECGs within 10 % mean , PR interval outside range 90210msec ECG suitable QT measurements A history elevate rest blood pressure mean blood pressure high 140/90 mmHg screen . A mean heart rate outside range 4090 bpm screen . History use tobacco nicotinecontaining product within 6 month screen positive cotinine test screening . The subject donate unit ( 400ml ) blood within 60 day screening , , intend donate study . The subject currently take regular ( course ) medication , whether prescribe , include herbal remedy St John 's Wort . The subject take : prescription medication within past 2 week prior dose , OTC medication ( except simple analgesic ) within 48 hour prior dose , unless judge Investigator compromise safety influence outcome study . The subject participate study new molecular entity within period 3 month prior dose . The subject test positive hepatitis C antibody , hepatitis B surface antigen HIV</criteria>
	<gender>Male</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Muscarinic Receptor Antagonist ,</keyword>
	<keyword>intravenous infusion ,</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>healthy subject ,</keyword>
	<keyword>safety ,</keyword>
	<keyword>tolerability ,</keyword>
	<keyword>Anticholinergic ,</keyword>
	<keyword>oral dosing ,</keyword>
</DOC>